Pulmonary Arterial Hypertension Clinical Trials

55 recruiting

Pulmonary Arterial Hypertension Trials at a Glance

58 actively recruiting trials for pulmonary arterial hypertension are listed on ClinicalTrialsFinder across 6 cities in 38 countries. The largest study group is Not Applicable with 13 trials, with the heaviest enrollment activity in Nashville, Durham, and Cincinnati. Lead sponsors running pulmonary arterial hypertension studies include Vanderbilt University Medical Center, Bastiaan Driehuys, and AOP Orphan Pharmaceuticals AG.

Browse pulmonary arterial hypertension trials by phase

Treatments under study

About Pulmonary Arterial Hypertension Clinical Trials

Looking for clinical trials for Pulmonary Arterial Hypertension? There are currently 55 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pulmonary Arterial Hypertension trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pulmonary Arterial Hypertension clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 58 trials

Recruiting
Phase 2

Spironolactone for Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension
National Institutes of Health Clinical Center (CC)70 enrolled1 locationNCT01712620
Recruiting
Not Applicable

Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions

Genetic TestingPulmonary Arterial HypertensionHeart Defects, Congenital
Universitaire Ziekenhuizen KU Leuven21 enrolled1 locationNCT02691689
Recruiting
Phase 1

Study of Intravenous ZMA001 in Healthy Subjects

Pulmonary Arterial Hypertension PAH
National Heart, Lung, and Blood Institute (NHLBI)96 enrolled1 locationNCT05967299
Recruiting
Phase 1Phase 2

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

Healthy Volunteers, Pulmonary Arterial Hypertension
Novartis Pharmaceuticals232 enrolled85 locationsNCT06649110
Recruiting
Phase 2

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC42 enrolled35 locationsNCT05587712
Recruiting
Phase 3

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC815 enrolled93 locationsNCT07218029
Recruiting

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Heart FailurePainInsomnia+22 more
Duke University5,000 enrolled51 locationsNCT04278404
Recruiting
Not Applicable

Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)

Pulmonary Arterial Hypertension
V-Wave Ltd20 enrolled5 locationsNCT03838445
Recruiting
Not Applicable

Mobile Health Intervention to Improve Exercise in Pediatric PH

Pulmonary Arterial Hypertension
Vanderbilt University Medical Center50 enrolled1 locationNCT06549452
Recruiting
Phase 1

A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension
China National Center for Cardiovascular Diseases72 enrolled1 locationNCT06554301
Recruiting

Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals

Idiopathic Pulmonary Arterial HypertensionHeritable Pulmonary Arterial HypertensionUnaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo+1 more
Vanderbilt University Medical Center150 enrolled1 locationNCT05584722
Recruiting
Phase 2

A Trial of "APL-9796'' in Adults With Pulmonary Hypertension

Pulmonary Arterial Hypertension
Apollo Therapeutics Ltd48 enrolled5 locationsNCT06846554
Recruiting
Phase 2

129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial HypertensionConnective Tissue DiseasesIdiopathic Pulmonary Arterial Hypertension+1 more
Bastiaan Driehuys20 enrolled1 locationNCT06104228
Recruiting
Phase 2

129 Xenon Imaging in Patients Treated With Sotatercept

Pulmonary HypertensionPulmonary Arterial Hypertension
Bastiaan Driehuys14 enrolled1 locationNCT06351345
Recruiting
Phase 2

Pulmonary Hypertension SOLAR

COPDInterstitial Lung DiseasePulmonary Arterial Hypertension
Bastiaan Driehuys30 enrolled1 locationNCT04778046
Recruiting
Early Phase 1

PET Image in PAH Patients

Pulmonary Arterial Hypertension
Stephen Y. Chan71 enrolled1 locationNCT05452889
Recruiting
Phase 4

A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy

Eisenmenger SyndromePulmonary Arterial Hypertension of Congenital Heart Disease
Kazuya Hosokawa36 enrolled10 locationsNCT07356778
Recruiting
Phase 1

Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults

Pulmonary Arterial Hypertension
Pharmosa Biopharm Inc.32 enrolled1 locationNCT06429930
Recruiting

Pulmonary Hypertension Association Registry

Pulmonary HypertensionPulmonary Arterial HypertensionChronic Thromboembolic Pulmonary Hypertension
Pulmonary Hypertension Association, Inc.3,000 enrolled52 locationsNCT04071327
Recruiting

Rutgers University Study of the Genetics of Pulmonary Hypertension

Pulmonary HypertensionPulmonary Arterial HypertensionPulmonary Arterial Hypertension of Congenital Heart Disease+5 more
Rutgers, The State University of New Jersey10,000 enrolled1 locationNCT07217522